Plantarc Bio Ltd.

Investor Presentation • Nov 18, 2020

Genes made byNature

Partial convenience translation only of the Company's investors Presentation published in Hebrew on 5.11.2020. The Appendices included in the Hebrew version is not included under this translation. The full and binding text is the one included in the presentation published in Hebrew as aforesaid.

Nov 2020

Disclaimer

This presentation is a partial convenience translation only to the Hebrew presentation published by the Company on 5/11/2020.

This presentation does not constitute an offer to invest or purchase securities and does not constitute an "Offer to the Public" or a "Sale to the Public". In addition, this presentation does not constitute a substitute for investment advice or investment marketing advice that takes into account the data and special needs of each person and / or investor and the data included in this presentation does not constitute a substitute for individual discretion and judgment of each potential investor.

This presentation is made for the purpose of providing general and non comprehensive information for convenience and concise purposes only. This presentation does not exhaustive and does not purport to encompass the full data about the Company and its activities and / or all information that may be relevant for the purpose of making any decision regarding investment in the Company's securities and in general.

For any details about the Company's operations, including the risks involve in its operations, please refer to the draft Completion Prospectus and Shelf Prospectus published by the Company in November 2020 (hereinafter: the "Prospectus Draft").

The information contained in this presentation is based on the information that included by the Company in the Prospectus Draft. However, this presentation may include additional data that is not a material information, including data that are presented differently in the characterization and / or editing and / or segmentation in relation to the data that contained in the Prospectus Draft. Also, since this presentation was made prior to the final drafting of the final Prospectus, there may be changes in the data presented in this presentation and the Company's reports must be followed.

For the avoidance of doubt, it is clarified that the Company does not undertake to update or change this presentation and / or to update or change data and / or forecasts and / or estimates included in it. This presentation includes in slides 12, 14-17, 19-24 forward-looking information as defined in the Securities Law, 1968 (Including information on estimated growth in target markets, expected marketing and sales of products, potential royalties and estimated periods for research and development processes). Such information includes, inter alia, forecasts, objectives, assessments and various estimates, including information provided by way of illustrations and / or graphs and / or tables relating to future events or matters, that the realization of which is uncertain and beyond the Company's control, and such information is based on its subjective assessment of the Company or based on public data. The realization and / or non-realization of the forward-looking information will be affected by factors that cannot be assessed in advance and are beyond the Company's control and therefore there is no certainty that it will materialize and it may materialize differently, including materially, from the manner presented in this presentation.

The Need

There is a continuous critical need for world crops yield improvement, due to:

• Increase in world population
• Less available arable land
• Climate instability
• Regulatory requirements to improve food quality

מקור: FAO

PlantArc Bio Roadmap

	Raising total ~15M NIS in 3 waves from same investors & Israel Innovation Authority grants
	DIP* technology development		Gene discovery and product development
2014	2015	2016	2017	2018	2019	2020
					Agreement with a	Agreement with
Formation			Application of first patent on DIP*	Forming Targene** with Seach	pronounced Indian Seed Comp.	one of the big 5 Seed Comp. and other
				Collaboration Agreements with:

*DIP=Direct In Plant

** Portfolio company not reported in financial statement

The team

Management & Key Team

Dror Shalitin (PhD) Founder & Co- CEO Director

Eldad Meshoulam Co- CEO

Roy Livneh (MBA) CBO

Noam Grimberg (PhD) CSO

Board members

Prof. Oded Shoseyov Chairman Hebrew University

Amir Biram CEO of JTLV

Shmulik Barashi Partner at Fortissimo Capital Group

Advisory Board

Todd Mockler (PhD) Donald Danforth Plant Science Centre.

Prof. Maurice Moloney Bill and Melinda Gates Foundation, advisor

Vision	Becoming world leading Gene Discovery company using our proprietary innovative IP protected technology
Active in	Since we established in 2014, we are active in R&D of gene discovery and improving important traits for plants (e.g. Drought res., Herbicide tol.), esp. for world agriculture
Products	The company is currently in advanced development of 6 products: 1) compound against the Red Palm Weevil 2) substance against soilborne disease and nematodes 3) biological compounds for yield increase 4) improving drought stress resistance in plants 5) herbicide tolerance plants 6) Gene discovery for production of APIs of cannabis* outside of the plant
End Customers	Our products shall be sold to worldwide Seed companies, Ag-chem companies and Plant Protection companies
IP	Five patents submitted on the gene discovery technology and other products achieved through it
Business Partnerships	6 business collaborations with world leading Seed and Ag-chem companies, holdings of 42% in Targene* in medical cannabis (together with Seach Medical Group ltd.)

*Portfolio company not reported in financial statement

DIP* technology Unique Gene Discovery process, IP protected

Implementing identified genes in 3 methodologies

Activities and Markets

3 Product families in development

• Eliminating the Red Palm Weevil
  • Yield enhancer in Canola
  • Soilborne Diseases & Nematodes protection
• Yield increase in more strains
• Elimination of more insects

• Drought resistance genes
• Herbicides resistance genes
• Additional herbicides resistance genes

• Commercial production in bioreactors:
  • Single molecules (CBD/THC etc')
  • cannabis cells with full spectrum
• Gene editing in Cannabis

* Activities in Targene

In

Development

Next stage

Strategic collaborations

* Activities in Targene

Target markets of ~\$73B (2019)

	1 Biological Yield enhancers and Crop protection RAi	2 Global seeds market	3 Cannabinoids market
Market Size* (CAGR)	\$8B (12.9%)	\$55B (7.6%)	\$10B (20%)
Specific demand	• RPW a global insect attacking palms of all kinds • Canola, a very large market of ~\$35B	• 77% of arable land not irrigated; \$10B annual drought damages in US • Herbicides resistance traits exists in most GMO seeds	• Today, all cannabinoids production relies on the plant itself, and suffer from lack of uniformity, depreciation and infections
			*Forward looking estimations. More details in slide 2; Source: Link 1 , Link 2, Link3, Link4, Link5, Link6

Details on products

1 Biological compounds and molecules

Compound for Eliminating the Red Palm Weevil

• Identified insect's genes for targeting for fatal affect of larva
• Patent submitted
• Successfully proved by feeding tests on larva; Experiments in trees still running
• Collaboration with the strategic partner Gadot-Agro, representing global CP companies
• Subjected to completing of R&D and licensing/regulation, we prospect market entrance in 2022*
• Estimated potential royalties of hundreds \$Ks in Israel and \$Ms globally

1א

1 Biological compounds and molecules

1B Yield enhancers in Canola

• RNAi based applications affecting crops genes, resulting in Yield increase
• Patent submitted
• Initial positive results during both greenhouse and field trials
• Subjected to completing of R&D and licensing/regulation, we prospect market entrance in 2023*
• Estimated potential royalties of \$Ms \$10sM yearly

1 Biological compounds and molecules

1C Soilborne Diseases & Nematodes protection

• Microbes enabling plant tolerance/resistance to diseases
• Proved by greenhouse experiments for various soilborne diseases
• Patent submitted
• being tested by one of the leading global CP companies
• Following successful tests, potential sales by 2023*

Less infection in Nematodes

2 Gene discovery for seeds improvement

Drought resistance genes

• Discovered drought resistant genes in the Dead Sea and desert areas
• Tests & Experiments:
  • Genes were tested in Tobacco with excellent results of increasing total weight by 30-70%
  • Agreement with global Indian Seed company for increasing drought resistance in Corn
  • In examination by a leading American company for Potato
  • In trial in Soybean in Wisconsin by the company, with initial very good results
• Estimated potential royalties of \$10sM yearly for every crop that a gene will be developed*

Increase crops size, Tabaco tests, Israel, April-July 2019

Trials results 2 2

Still in progress

*STAYGREEN ** Index for measuring crops wilting levels in the range of 0-4 (4-high wilting)

Initial successful results in Soy, Wisconsin, Oct/Nov 2020 Engineered plants shows strong Stay Green* effects, an important trait for agriculture Genes assessment in Corn by an Indian corp. Results in Tabaco

2 Gene discovery for seeds improvement

2B Herbicides resistance genes

• Discovered novel genes (patent protected) enabling plants resistance to a wide range of herbicides
• Tests & Experiments:
  • Genes were tested successfully in various model plants
  • One of the leading genes is being tested by KWS, one of the biggest Seed Companies globally
• Estimated potential royalties of \$10sM yearly for every crop that a gene will be developed*

Identifying genes for producing active ingredients of Cannabis

(through Targene)*

3

Targene was established during 2018 and since is working to produce the Cannabis Active Ingredients through a constant process

• Entering the cannabinoids genes pathways into a new organism, enabling the production of APIs such as CBD, THC etc.
• Use of Bioreactors for the production and controlling of the amount and timing of the APIs expression
• To date we have achieved:
  • Growing several liters from different lines of cannabis cells in bioreactors
  • Preparation of the new organism for expressing cannabinoids
  • First cannabis plants that shall enable gene editing production

Success of producing the APIs in a sterile, fast and constant way shall revolutionize the Medical and Pharma industries

*To this date Targene is held by PlantArcBio (42%), Seach Medical Group (53%) and other (5%)

Business model and Roadmap

Business model*

Summary of products in development

	Product	Collaboration	Achievements	Estimation of potential royalties*
1	Compounds for controlling the RPW		100% larva death, promising results in trees	Few \$M
	Yield increase in Canola		Initial good results for Canola field trials	Few – Dozens of \$M
	Disease& nematodes protection	One of the world leading plant protection companies	Initial good results by external testing by the partner	Will be assessed later with our partner
2	Drought resistant genes	Leading Indian Seed Comp in Corn and internally in Soy	Good results in Tobacco, Initial good results in Soy in USA	Dozens for each strain
	Herbicide resistant genes		Resistance for several herbicides in various plants	Dozens for each strain
3	Active Ingredient production (Targene)		Growth of several liters of cannabis cells. Developing expression in new organism	Hard to assess currently

Roadmap*

Unlocking commercial potential with long-term growth

Use of capital raised

Implementing strategy to commercialize activities

Expending scientific team

Assessing genes in target strains to accelerate commercialization

Accelerating global partnerships

Financing companies activities

In addition, it will allow investment in new capabilities and technologies

Thank You

Attractive investment

Attractive timing Unique technology Strategic partners

Attractive markets

Wide product portfolio Strong leadership

Professional background of management and advisory teams

• Holds a PhD in Plant Molecular Biology and Physiology from the Hebrew University of Jerusalem
• Post doctorate at UCLA on plant photoreceptors
• Senior Investigator at the Institute for Myeloma and Bone Cancer Disease, USA
• Leading Researcher at Evogene, lead R&D projects with global Seed Companies such as Syngenta, Corteva

Eldad Meshuolam

• BA in Data Management, MBa in Business Administration from the IDC Herzliya
• Served 12 years as an Officer in the IDF Air Force
• Project Manager in the global Advisory Firm BCG, where he advised leading managements and firms in the Israeli market, amongst big and global agricultural companies

Prof. Oded Shoseyov

• Prof. of the Hebrew University of Jerusalem, in the field of Plant Mol. Biol., Protein Engineering and Nano Biotechnology
• Published more than 300 Scientific papers and Inventor of 92 patents
• Won distinguished awards, such as Pollak (2002) and Key (1999, 2010) for innovation and applicable science
• Founder of 15 companies such as ColPlant and Futuragene

Dr. Dror Shalitin Prof. Maurice Moloney

• Plant molecular biology scientist.
• Advisor to the Bill & Melinda Gates Foundation
• One of the first responsible for the transgenic Canola, as a group leader in Calgene Inc.
• Senior executive leader as CEO / Exec. in 3 strategic research organizations, inc. CSIRO and GIFS
• Over 300 patents

Dr. Todd Mockler

Scientific Member & Principal Investigator, Donald Danforth Plant Science Centre.

Founder and ex CTO of Benson Hill. Geraldine J. and Robert L. Virgil Distinguished Investigator Award

27